BIOSECURE returns to US pharma agenda with 2.0 update
The latest amendment, which has been endorsed by Congress, could be the Act’s catalyst after a year in legislative limbo.
The latest amendment, which has been endorsed by Congress, could be the Act’s catalyst after a year in legislative limbo.
